Additional Study Information: This is a clinical research study for subjects with Acute Myeloid Leukemia (AML) who have not received any treatment for their disease and who are over the age of 60. These patients will be treated with low-does cytarabine in combination with Lintuzumab-Ac225. Low dose cytarabine has been investigated in elderly AML patients for at least two decades and is widely considered as acceptable standard of care in this population. Cytarabine has been approved by the FDA for the treatment of specific types of leukemia, including AML.